This will be a rapid fire series of short presentations of newest information on the diagnosis, pathogenesis and treatment of pemphigus, pemphigoid, epidermolysis bullosa aquisita and dermatitis herpetiformis. New therapeutic options and their mechanisms of action will be reviewed along with recently identified causes for several of the autoimmune bullous diseases. Speakers will include a broad spectrum of internationally recognized experts in the field.
Dr. Fivenson / Introduction
Dr. Joly / Rituximab in Pemphigus- Who and When?
Dr. Murrell / Bruton Tyrosine Kinase Inhibitors for Pemphigus
Dr. Caux / FcRn, CAART and Other Emerging Treatment Options for Pemphigus
Dr. Diaz / Endemic Pemphigus Foliaceous IgG4 Autoantibody Targets That Lead to Acantholysis
Dr. Grando / Multimodal Treatment of Pemphigus = Multi- vs Monofactorial Pathogenesis
Dr. Feldman / Biomarkers for Pemphigus
Dr. Diaz, Dr. Murrell, Dr. Feldman, Dr. Grando, Dr. Caux, and Dr. Joly / Pemphigus Panel Q & A
Dr. Werth / Rituximab for other AIBDs
Dr. Zone / The Role of Transglutaminase 3 in Dermatitis Herpetiformis Skin
Dr. Woodley / Epidermolysis Bullosa Aquisita Update - New Consensus Paper
Dr. Fairley / IgE Pemphigoid
Dr. Prost Squarcioni / Drug - Induced AIBDs - PD-1, PDL-1, ACEi, PPi, DDP4i
Dr. Aoki / Epitope Spreading in PAMS: A Clinical Immunopathologic Basis